Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

Abstract

Inhibitors of the PD-1-PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little is known about the immunological alterations that occur in human cancer tissue after PD-1 blockade. We developed and employed a patient-derived tumor fragment platform to dissect the early immunological response of human tumor tissue to ex vivo PD-1 blockade. We observed that the capacity of immune cells to be reactivated ex vivo was predictive of clinical response, and perturbation analyses identified tumor-resident T cells as a key component of this immunological response. In addition, through combined analysis of baseline properties and immune response capacity, we identified a new subgroup of infiltrated tumors that lacks the capacity to respond to PD-1 blockade. Finally, the baseline presence of tertiary lymphoid structures and their components correlated with the capacity of cancers to undergo intratumoral immune cell reactivation.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01398-3

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 53 references

Cited by

See all 420

Metadata

Authors
Voabil, P., de Bruijn, M., Roelofsen, L. M., Hendriks, S. H., Brokamp, S., van den Braber, M., Broeks, A., Sanders, J., Herzig, P., Zippelius, A., Blank, C. U., Hartemink, K. J., Monkhorst, K., Haanen, J. B. A. G., Schumacher, T. N., & Thommen, D. S.
Affiliations
  • The Netherlands Cancer Institute (NL)
  • Leiden University Medical Center (NL)
  • University Hospital of Basel (CH)
Corresponding author
Thommen, Daniela S.
Venue
Nature Medicine
Published
2021-07
Volume
27
Issue
7
Pages
1250-1261
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3180646962
Cited by
380
References
53
Citations by year
2026: 74 · 2025: 82 · 2024: 73 · 2023: 73 · 2022: 65 · 2021: 11
FWCI
20.46
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
anti-PD-1 therapy, PD-1/PD-L1 axis, tumor-infiltrating T cells, tertiary lymphoid structures, tumor immunology, immune checkpoint inhibitors
MeSH terms
Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Cell Differentiation, Humans, Lymphocyte Activation, Neoplasms, Cytokines, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. https://app.cochat.ai/papers/10.1038/s41591-021-01398-3
The paper
Voabil, P., de Bruijn, M., Roelofsen, L. M., Hendriks, S. H., Brokamp, S., van den Braber, M., Broeks, A., Sanders, J., Herzig, P., Zippelius, A., Blank, C. U., Hartemink, K. J., Monkhorst, K., Haanen, J. B. A. G., Schumacher, T. N., & Thommen, D. S. (2021). An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature Medicine. https://doi.org/10.1038/s41591-021-01398-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.